Phase 2 Motor Neurone Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with amyotrophic lateral sclerosis (ALS) according to the Gold Coast Criteria (2020)
• People aged 18 or older, of any gender
• People whose ALS breathing-related symptoms score at least 1 point on a standard ALS rating scale (ALSFRS-R) across three breathing-related measures: shortness of breath, breathing while upright, and breathing problems generally
• People who have been taking a stable dose of riluzole tablets for at least 7 days before the study starts, and who are able to continue taking it until the final study visit
• People who are willing to take part, able to sign a consent form, and able to follow the study procedures

Who may not be able to join:

• People who are known to be allergic to the study drug or any of its ingredients
• People who have another illness or injury that would interfere with assessments or be life-threatening, or who have serious irreversible disease of the heart, lungs, liver, or brain, or who have multiple organ failure (note: people with a specific type of breathing failure — type I or type II respiratory failure — are also excluded; confirm details with trial site)
• People who have a significant mental health condition or problems with thinking and memory
• People who have had a moderate or major surgery within one month before the screening period
• People who have taken part in another clinical trial within the past month
• People who are pregnant or breastfeeding
• People whose ability to follow the study requirements is considered a concern, or where the research team identifies any other reason that makes participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.